Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The tape was painted at 4 pm. Several bids at $.49 and ask was $.495. Someone doesn't want this thing to move yet. Could it be the R&R boys?
Also expecting the pregame excuses to start coming from BOT. "Here's what I hear:
1. The dog ate the Duke paper
2. We really meant the Dukes of Hazard
3. The monkeys formed a union and went on strike
T minus 8 days for a Duke publication or other publications that mgmt talked about in the last CC and the investor presentation. Hopefully they deliver the goods and the goods live up to the billing. Mgmt's credibility has already been shot so they really can't lose it. They can slowly start regaining it which will be needed to get the delisting issue behind them. They really need institutional interest at this point. Not going to happen in this risk averse market unless mgmt starts delivering.
What I find interesting is SK saying the interest level in the bavi anti viral for both flu, dod and hiv and the programs have been extremely active. Also grants etc have funded the research. Why has this been kept quiet? Seems to me SK and the IB crew don't want this thing to run just yet.
Good comparison - PPHM shareholder and POW. There might be more hope for a POW.
Gotta go thru $4 before you get to $20.
So far not too bad. Was expecting much worse. My aspirations for a big pop have faded. A respectable buyout at a decent number will work. The number is far off the poison pill number.
OT Still watching CNBC, several foreign currency experts are saying we could see a 1929 style run on the US banking system. They're saying the fed must navigate through this mess or we're screwed.
Watching CNBC hoping we dodge a bullet tomorrow and PPHM doesn't get hammered too much. Could be that the market turmoil forces PPHM mgmt to do something sooner than later. Given the dollar's weakness, perhaps a european company or asian company could step up.
I think mgmt has chosen the all or nothing path cause they own virtually nothing in the way of share ownership.
Jazz,
What's your take on this analysis? Check out her resume and other reviews. She also worked for the FDA.
http://www.glgroup.com/News/Bavituximab--Not-As-Targeted-an-Antibody-as-Its-Peers-8807.html
Unless the evidence is compelling and there is motivation by both paties to settle. If the evidence is so good for PPHM, CTL would be motivated to settle now given PPHM's dire need for cash and to conserve cash cause lawsuits cost money. If CTL waits too long and PPHM solves the cash flow issues, the cost of settlement could go up substantially. All IMO.
Even if the Duke paper comes out, I think there will still be a cloud hanging overhead regarding the financing issues and capital requirements. One could argue that the Duke paper will draw attention to the great technology and at the same time draw attention to the fact that this great technology on the viral front is sitting on the bench due to lack of resources. In the meantime all the potential partners are licking their chops waiting for the buzzer hoping they get a desperation deal. Hopefully mgmt is savvy enough by now (doubt it) and they have a backup plan. I've seen it too many times where you walk down the aisle and at the altar the deal changes or gets stalled.
I'd say the India trial delay cost us 3 months of that "wait 6 months". Hopefully we're heading towards the barn.
Jazz,
What's your guess on which publication covers the Duke stuff and when?
Thx
Common sense. If you were surrounded by tremendous resourses and you had to ask for lunch money every month, would you think about it.
That's the problem Jazz. If the technology is so promising, why is it sitting on the bench. UT Southwestern is part of the UT system which has tons of money. I'm sure Thorpe sees this and is asking why am I developing world class potentially ground breaking stuff and I'm dealing with a third world type operation. Why does he need PPHM?
PL said they have been in talks with 40 companies over the last two months. Hopefully they are making something happen. I would like to get an understanding of what "talks" means. Does a handshake at a conference count as "talk". Kinda like depends on what "is" is.
Mgmt has little skin in the game and they get decent paychecks. Why would they be inclined to max current shareholder value when they really are not big shareholders? Do they wait for the last 30 seconds of the fourth quarter and throw the hail mary pass?
I can also recall some language about preclinical stuff that is being put on hold.. we are motivated... as soon as we get resources... looking forward....
The pipeline has too much potential to be held down by lack of resources by the current mgmt.
Sick of hearing .... we're in talks...
BOT what's your take on the CC? Are things still looking up?
I also got the impression that mgmt is against the ropes in the 10th round and they are trailing on the scorecards. What will be the value drivers near term to get the stock above $1.00 before July? What are the strategic implications for selling Avid? Paul's comments that is so valuable to the company, than why sell it? I don't think they provided good answers today. They need to do a partner deal sooner than later IMO. Also, I would hope that the Duke paper lives up to mgmt's hype.
The company needs to be sold as sson as some good phase II data comes in. You can't have all that potential sitting on the bench. My guess is Thorpe feels the same way.
With (no) respect to the FDA, how much is science and how much is political influence by way of greasing the palms of politicians.
Sure acting like a pipe or someone knows something and it's not good.
As posted earlier by several astute traders, stops have been taken out from "prudent" investors that protect their downside. Unfortunately, with such a slim following and no institutional base, it doesn't take much to shake this tree. It seems to me tahe everytime we move the PPS down a few cents, we get 100,000 shares of volume which were probably the stops.
With the overall weakness in the market and probably some margin calls across the market, no one is coming to the rescue.
If that's the case we should be going up in price, not down. Under accumulation? I think so.
I think the objective is to take out the 10% stops very quickly, usually mid morning when folks are busy at work.
Another shakedown in progress. All good signs IMO.
Shake that tree one more time for me. I'll be ready this time.
Just waiting for the flop. And I'm all in.
Jazz,
Good presentation. Where would Avastin or Erbitux be on those graphs?
Thx
DNA boosts market cap by about $6 bil from FDA approval of Avastin for breast cancer in combo with chemo. Jazzman, correct me if I'm wrong but Avastin wasn't all that great in extending survival times. Just think where bavi could lead us if the trials prove efficacy.
agree. still need institutional accumulation which means the games have to be played.
Looks like our friends thru CINN think the party's getting out of hand. "These people are having too much fun - stop dancing and turn the music down."
Mind games. Someone doesn't want the ship to leave the dock just yet. Small price to pay to keep the fear factor up.
This tells me that some R&R clients have established their positions. Hopefully more to follow.
Who let the dogs out? Will they be put back in the kennel at close? Is word getting out?
It all comes down to results of phase II. The market will value based on market cap and not price per share. Look at REGN, OSIP, IMCL etc. If bavi and cotara can hold a candle to the drugs those companies offer, I can see a significant increase in market cap. Look at the chart previously posted which shows value increasing as phase II approaches completion (assuming results are good). Given bavi's broad application potential, the increase could be even bigger.
Use the ignore feature. It works.